Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tutogen grows top-line by 42% for 2007:

This article was originally published in Clinica

Executive Summary

Trading in Tutogen Medical shares began the week on a positive note after the Alachua, Florida-based biological implants manufacturer announced solid results for its fiscal year 2007. Revenues soared 42% to $53.8m, helped by a 92% increase in sales of spinal products and a 65% increase in sales of surgical specialty products. The firm also benefited from a $4.2m tax benefit, which boosted net income to $6.8m. Excluding this one-off gain, net earnings were $2.6m, compared to a loss of $0.6m in the previous year. Tutogen is currently in a pending merger agreement with fellow biologics implant company Regeneration Technologies (see Clinica No 1283, p 14). Completion of the stock-for-stock transaction, valued at $263m, is expected in March 2008.

You may also be interested in...

Pandemic-Related Price-Gouging Would Be False, Misleading Advertising Under House, Senate Bills

House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.

COVID-19 Trial Changes Are “Propulsive Force” For Digital Adoption

Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.

Digital Doublespeak: The Language Barrier When Tech Companies Meet Regulators

A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts